Trends in response rate and survival in small-cell lung cancer patients between 1997 and 2017

Abstract

IntroductionMedian survival of small-cell lung cancer (SCLC) patients is usually around 1 year. The advent of new drugs may have slightly improved their prognosis. We aimed to assess whether SCLC response to chemotherapy and survival had changed over time. MethodsConsecutive SCLC patients were included at Grenoble University Hospital, France. We compared the patients’ characteristics, response to chemotherapy and survival between 1997–2009 (period 1) and 2010–2017 (period 2). ResultsA total of 529 patients were identified, of whom 498 received a first line of chemotherapy and 279 a second line. The majority (n = 290, 58%) had extensive disease. The objective response rate (ORR) to first-line chemotherapy in metastatic patients was 63% in period 1 and 62% in period 2; the ORRs to second-line chemotherapy were 39% and 29%, respectively. Median overall survival from first-line chemotherapy was 13.2 months (interquartile range [IQR] 7.4–24.4) in period 1 and 11.2 months (IQR 7.1–21.2) in period 2. Mortality in these two periods did not differ significantly even after adjustment for prognostic factors (hazard ratio [HR] = 0.82, 95% confidence interval [CI] 0.66–1.00). The factors independently associated with death were cardiovascular comorbidities (HR = 1.28 [95%CI 1.05–1.55]), liver comorbidities (HR = 1.31 [95%CI 1.03–1.65]), poor ECOG performance status (3–4vs. 0–1, HR = 2.45 [95%CI 1.83–3.30]) and extensive disease (HR = 2.69 [95%CI 2.18–3.33]). ConclusionsSince 1997, there has been no improvement in the survival or response rate to chemotherapy of SCLC patients. There is a desperate need for new approaches in this setting.